Valuation: ARPIDA

Market Cap 16.8M 20.48M 18.29M 15.26M 28.66M 1.94B 29.38M 201M 80.69M 1.02B 76.85M 75.21M 3.24B P/E 2024
6.22x
P/E 2025 -8.95x
Enterprise Value 10.9M 13.28M 11.86M 9.9M 18.59M 1.26B 19.05M 130M 52.33M 664M 49.84M 48.78M 2.1B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
62.03%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact 59 -
Director TitleAgeSince
Chairman - 2025-03-26
Director/Board Member - 2025-03-26
Change 5-day change 1-year change 3-year change Capi.($)
Average
Weighted average by Cap.

Financials

2024 2025
Net sales - -
Net income 1.04M 1.27M 1.14M 948K 1.78M 120M 1.82M 12.46M 5.01M 63.59M 4.77M 4.67M 202M -653K -795K -711K -593K -1.11M -75.34M -1.14M -7.79M -3.13M -39.77M -2.99M -2.92M -126M
Net Debt -6.75M -8.23M -7.35M -6.13M -11.52M -780M -11.81M -80.61M -32.43M -411M -30.89M -30.23M -1.3B -5.91M -7.2M -6.43M -5.36M -10.07M -682M -10.33M -70.49M -28.36M -360M -27.01M -26.43M -1.14B
Logo ARPIDA
EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Employees
-